Itraconazol Actavis

Itraconazole, the active ingredient in Itraconazol Actavis, is a triazole antifungal presented as an oral formulation for systemic use. It treats a range of fungal infections, including deep systemic mycoses, skin and nail infections, and is used for prophylaxis in patients with weakened immune systems.

GNH USA supplies Itraconazol Actavis as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Itraconazol Actavis is indicated for fungal infections affecting various organ systems.

- Systemic mycoses (e.g., blastomycosis, histoplasmosis, aspergillosis): treatment of deep fungal infections. - Dermatophytosis: eradication of skin fungal infections. - Onychomycosis: clearance of fungal nail disease. - Prophylaxis in immunocompromised patients: prevention of opportunistic fungal infections.

Itraconazole may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea or vomiting - Abdominal pain or dyspepsia - Headache - Rash or pruritus

Serious or Rare Side Effects: - Hepatotoxicity (elevated liver enzymes, hepatitis) - Congestive heart failure exacerbation - Severe hypersensitivity reactions (anaphylaxis, Stevens‑Johnson syndrome)

When prescribing itraconazole, several safety considerations should be observed. - Assess liver function: obtain baseline hepatic enzymes and monitor periodically. - Avoid use in patients with known hypersensitivity to azole antifungals. - Monitor cardiac status: contraindicated in patients with existing heart failure. - Review concomitant medications: many drugs interact via CYP3A4 metabolism. - Store at room temperature: keep in the original container, protect from moisture and light.

Itraconazole interacts with several medicines through metabolic pathways.

Major Interactions (Avoid): - Rifampin, rifabutin, or other strong CYP3A inducers: markedly reduce itraconazole exposure. - Ketoconazole or other azoles: additive hepatotoxicity risk. - Macrolide antibiotics (e.g., erythromycin, clarithromycin): increase itraconazole plasma levels, risk of toxicity. - St. John’s wort: induces metabolism, decreasing efficacy.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, requiring INR monitoring. - Statins metabolized by CYP3A4 (e.g., simvastatin, lovastatin): increased risk of myopathy. - Other CYP3A4 substrates (e.g., midazolam, cyclosporine): may need dose adjustments. - Calcium channel blockers (e.g., verapamil): possible increased levels.